Volume 15 - Issue 9 - September 2002
Onychomycosis is a common nail infection, which is often chronic, difficult to eradicate and tends to recur.1 Current therapeutic approaches include mechanical or chemical avulsion, topical therapy, oral therapy or a combination of one or more of these treatment modalities. Treatment of onychomycosis has improved greatly with the addition of broad-spectrum oral antifungal agents and topical nail lacquers. However, even with the therapeutic advances, onychomycosis continues to increase in prevalence, treatment is not always successful, and relapse and reinfection may occur even after
All medical practices are essentially small enterprises, not very different from any of the Fortune 500 companies. Practices generate revenue by providing services or selling products. They also have expenses for staff, rent, equipment and insurance. There are also elements of marketing, finance, human resources, etc. Like all companies, podiatric practices are challenged by inefficiency and the desire to continue improving on their profit margins.
When the typical private practitioner hears phrases such as “Quality Improvement,” “Total Quality Management (TQM)” or “Process Enhancem
Statistics from the American Diabetes Association (ADA) reveal there were 86,000 amputations due to complications from diabetes mellitus in 2000. The ADA also points out that 50 to 70 percent of these patients will develop peripheral neuropathy sometime in the course of their disease.1
The most widely believed paradigm in mainstream medicine today is that loss of sensation in diabetic peripheral neuropathy is irreversible and the only treatment available is the achievement of euglycemic control and the ancillary use of medicines such as Elavil and Neurontin.2 Sadly, this
Editor's Perspective »
The pursuit of a better testing method for diabetic peripheral neuropathy has spurred the re-emergence of the Pressure Specified Sensory Device (PSSD) and accompanying debate over its potential utility.
Yes, the NCV test and the Semmes-Weinstein monofilament allow you to test for the presence of neuropathy. However, in his article, “Restoring Sensation In Diabetic Patients” (see page 38), Stephen Barrett, DPM, says the monofilament does not “quantify or stage the level of peripheral neuropathy” and neither test enables you to assess “early stages of isolated peripheral nerve compres
I usually enjoy my work. My office is efficient. The patients appreciate our help. My staff is like family. Most weeks go by fast and end upbeat. Last week was an exception. The efficient office self-destructed when the computer medical billing program died. Something corrupted all the financial data and it vanished. The backup tapes were disabled. Neither the software support guy nor the hardware technician could bring it back to life.
The vascular surgeon with whom I have shared space for the past four years suffered a major bout of burnout and left practice last week. He is 44 and looks 60
It was with great incredulity that I read the article by Dr. Barrett entitled “A Closer Look At Endoscopic Plantar Fasciotomy” (see the May issue, pg. 38). He writes: “Prior to the development of endoscopic foot surgery, there was a strong desire not only to find a better, less invasive method to treat … plantar fasciitis surgically … Indeed, the standard of care … has changed radically since the … EPF.”
The inference here, of course, is that after EPF, that desire has been fulfilled and it is now the standard of care. The truth is that in the facilities where I perform surger